Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | UTRN | P46939 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834631 | 0.87 | NPC1 (0.60) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5834540 | 0.85 | NPC1 (0.56) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5834747 | 0.85 | RAB9A (0.58) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5834655 | 0.85 | NPC1 (0.60) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5834268 | 0.84 | NPC1 (0.61) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL6681482 | 0.84 | NPC1 (0.64) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5834155 | 0.83 | NPC1 (0.58) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5834845 | 0.83 | PTGS2 (0.53) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5835809 | 0.82 | NPC1 (0.75) | NPC1RAB9APTGS2MAPTALDH1A1 | |
| SCHEMBL5835099 | 0.82 | NPC1 (0.57) | NPC1RAB9APTGS2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | disclosed |
| EP-1483261-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 | NPC1 2102/4885RAB9A 1209/4885PTGS2 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.